State Health Department Adds New Organizations to Medical Marijuana Program


The Board is accepting public comment on the draft medical marijuana dispensary districts until August 11th.

Fiorello Pharmaceuticals, a Manhattan-based company, will operate a manufacturing facility in Schenectady County and dispensing facilities in Nassau, Monroe, New York and Saratoga counties.

Prescription strength: New York State has licensed five new medical marijuana companies to open dispensaries, including as many as four on Long Island.

As of the other state agencies responsible with overseeing the Ohio Medical Marijuana Control Program, the Board of Pharmacy determines dispensary locations.

"The supply has never been the problem", said Patrick McCarthy, spokesman for the Medical Cannabis Industry Alliance made up of the original five companies. The company's dispensaries will be in Erie, Orange, Queens and Suffolk counties.

And Ulster County-based PalliaTech NY, a subsidiary of Massachusetts-based biotech PalliaTech, will dispense in Nassau and Queens, as well as Orange and Clinton counties.

All five of the new companies will manufacture the product at facilities upstate, but have dispensaries in different parts of New York City and elsewhere throughout the state.

Citiva Medical, which will manufacture in Orange County and operate dispensaries in Dutchess and Chemung counties, as well as Brooklyn and Staten Island.

Right now, there are more than 25,000 patients and more than 1,100 registered practitioners participating in the medical marijuana program.

Other recent enhancements to New York State's Medical Marijuana Program include adding chronic pain as a qualifying condition, permitting home delivery, empowering nurse practitioners and physician assistants to certify patients and publishing a list of registered practitioners who have consented to be listed publicly.

The announcement comes as the state works to increase access to medical marijuana across the state.

Looking to make its medical marijuana program available to more New Yorkers, the state will double the number of companies that manufacture and distribute the drug.